Risk factors guide assessment, not a glaucoma diagnosis. The German screening intervals concern people without known glaucoma; manifest disease and diagnosed ocular hypertension need individual follow-up.
Terminology and draft status
Terminology review is not complete. No new WHO UMD entry verification is claimed for this copy; pending entries and limits are recorded in terminology.md.
01Define the clinical question and the evidence
Open-angle glaucoma involves progressive neuroretinal rim and retinal nerve fibre layer (RNFL) loss with corresponding visual-field damage. Early symptoms may be absent; risk assessment, detection, treatment and follow-up all contribute to care, so risk quantification is not the only means of preventing disability. 1 2
The original symptom figures, 26% without symptoms and 54% reporting blurred patches despite field loss, describe selected patients and definitions. Its 8-fold association with no eye examination within 2 years is not a causal guarantee that a fixed interval prevents blindness; the underlying studies remain to be appraised. 1
The DOG/BVA S2e update dated 3 March 2024 addresses adult risk and early detection, largely using populations of European ancestry; it does not set management for known glaucoma or diagnosed ocular hypertension. A strong A recommendation can coexist with evidence level 3 and expert consensus; Oxford 2011 levels and A/B/0 grades answer different questions. 2
02Keep incidence, prevalence and ancestry distinct
The original summarises 5-year incidence at age 40–80 as 0.5–1.5%, with Blue Mountains/Rotterdam about 0.5–0.6%, Salzburg-Moorfields 1.0% over 5 years and northern Sweden 0.9% per year. These heterogeneous ages, endpoints and periods cannot be pooled or converted into one annual risk; source-specific primary reports remain needed. 1
Prevalence increases with age; the original 2.0–2.5-fold increase per decade from age 40 and 1.3-fold male prevalence are group associations, not individual forecasts. First-degree family history is associated with about 2.0–3.0-fold risk, but reporting and ascertainment affect the estimate. 1 2
The original approximately 3-fold estimate for darker-skinned populations and earlier onset, and rising risk with age in Latin American populations, need population-specific context. Skin colour is an imprecise proxy for ancestry and social factors; do not infer an individual genetic risk or a universal coefficient from appearance. 1 2
The export gives Blue Mountains 0.5% and Rotterdam 0.6% over 5 years, but Ponza 3.8% over 12 years. Its European age-40–80 prevalence estimates, 2.93% for all glaucoma and 2.51% for open-angle glaucoma, are population summaries; the claimed Gutenberg confirmation requires its own denominator and definition. 1
| Age, years | Original prevalence estimate |
|---|---|
| 40 | 0.4% — original age-stratum estimate, not personal risk |
| 50 | 0.7% — original age-stratum estimate, not personal risk |
| 60 | 1.4% — original age-stratum estimate, not personal risk |
| 70 | 2.7% — original age-stratum estimate, not personal risk |
| 80 | 5.3% — original age-stratum estimate, not personal risk |
| 90 | 10.0% — original age-stratum estimate, not personal risk |
03Interpret pressure and disc findings in context
Intraocular pressure (IOP) is the established treatment target, but high IOP is not synonymous with glaucoma. OHTS randomised 1636 selected patients aged 40–80 without glaucomatous damage, with IOP 24–32 mmHg in one eye and 21–32 in the other. At 60 months estimated glaucoma incidence was 9.5% with observation versus 4.4% with medication: HR 0.40, 95% CI 0.27–0.59. 1 3
The rounded 9% in related earlier teaching and the 9.5% in this export concern the selected OHTS population, not every eye ≥24 mmHg. The 9.5% is a Kaplan–Meier estimate, not the raw 89/819=10.9% proportion; open treatment, masked endpoint assessment, attrition and allocation deviations matter. The CCT-adjustment study concerns risk prediction, not tonometer accuracy; central corneal thickness does not justify a universal corrected-IOP formula. 3 4
Cup-to-disc ratio (CDR) ≥0.6 at an average-sized disc or inter-eye asymmetry ≥0.2 increases suspicion; the latter LR 3.9–4.1 is a diagnostic likelihood ratio, not a future-risk multiplier. Disc haemorrhage original 7.5-fold refers to prevalent association, not guaranteed progression; disc size, rim, fields and imaging must be assessed. 1 2
Myopia of magnitude ≥4 dioptres, conventionally ≤−4 D, and pseudoexfoliation (PEX) deserve closer assessment. Original estimates 2.3-fold for myopia and 4–6-fold for PEX depend on population and design and should not be multiplied together as an individual risk score. 1 2
Original CDR ≥0.6 has LR 7.0–7.5; asymmetry ≥0.2 has LR 3.9–4.1 and ≥0.3 LR 7.3. These diagnostic likelihood ratios modify pre-test odds, not an individual future incidence; the original 1.5-fold association per mm axial length and 2–4-fold age effect after 50 also require study-specific context. 1
04Ask about the route and preparation of steroids
Topical ocular, intravitreal and systemic steroids can raise IOP. The original up to 79% after 2.1 mg fluocinolone is a historical preparation- and definition-specific estimate; it does not describe every current implant, steroid response or glaucoma incidence. 1 2
The guideline discusses inhaled high doses, historically >4 puffs for at least 3 months, especially with family history. Different inhalers deliver different doses; this is not a safe no-risk threshold. Its intranasal review found no clinically important group increase, which does not prove zero individual risk or justify changing systemic treatment without coordination. 1 2
The original diabetes/hypertension associations of 1.16–1.4 require study-specific interpretation. Shared age and vascular factors, ascertainment and more frequent examinations can confound associations; neither condition proves a glaucomatous optic neuropathy. 1 2
The export contrasts IOP rise in 15% after dexamethasone 0.7 mg with 79% after historical fluocinolone 2.1 mg. These are different preparations, definitions and populations, not a head-to-head estimate or a universal glaucoma rate. 1
05Offer screening with realistic expectations
DOG/BVA recommends offering screening from age 40, including binocular disc examination and IOP; recommendations 4-3 and 4-4 are strong but have evidence level 3. The historical 64% sensitivity/96% specificity estimate has selection/definition limits, including classifying IOP <18 mmHg as healthy; it is not universal test performance. 2
The Swedish screening follow-up reported blindness RR 0.52 over about 20 years after one screen at age 50–80. This observational follow-up is not the randomised EMGT treatment effect or proof that screening halves every individual risk. Discuss false positives, missed disease and the need to confirm a result. 1 2
A single IOP value cannot exclude OHT or glaucoma. The cited 5.3–6.9 mmHg between-day variation concerns a selected measurement series, not a universal instrument error. Suspicion leads to repeated IOP, perimetry, structural assessment, gonioscopy and pachymetry as appropriate before a treatment decision. 1 2
06Use intervals as consensus guidance, then confirm the diagnosis
The interval table preserves the four original risk groups. These are 2024 German expert-consensus screening intervals after excluding glaucoma, not a schedule for symptomatic patients or established disease. Relevant additional factors include first-degree family history, myopia magnitude ≥4 D, ancestry context, IOP 22–25 mmHg interpreted with CCT, borderline CDR/asymmetry and prolonged ocular/systemic steroids. 2
The original quick-review A/B labels are retained as export labels, not certified as separate recommendations for each association. The guideline bases intervals on combined risk and age; men do not receive a different interval solely because their average prevalence is higher. Explain a positive screen, confirm or exclude disease, document the next visit and individualise when necessary. 1 2
Recommendation 4-13 describes screening below age 40: 1 additional factor every 5 years, 2 factors every 2–3 years, ≥3 annually. Recommendation 4-14 gives at least annual screening for PEX or IOP >25 mmHg; these are consensus early-detection schedules after clinical assessment, never permission to wait with symptoms or suspected disease. 2
| Factor | Clinical meaning | Original number and limit | Screening implication | Export evidence label |
|---|---|---|---|---|
| Age | Incidence and prevalence rise | 2–4× after 50; 2–2.5× per decade after 40; group association | 40–59: 5 years; ≥60: 2–3 years without added factors | 3-1/3-7, level 1; labels require source context |
| First-degree family history | Ask which relative and diagnosis | About 2× incidence, 3× prevalence; ascertainment matters | Shorten according to combined risk | 3-3/3-10, level 2 |
| IOP | OHT is not glaucoma | Original ≥24 mmHg / 9.5% in 5 years refers to selected OHTS, not everyone | >25 mmHg at least annually after assessment | 3-4, level 1; OHTS |
| Myopia | Magnitude ≥4 D, usually ≤−4 D | Original 2–3× and 1.5× per mm are study-specific | Shorter interval with added risk | 3-5, level 2 |
| PEX | Important clinical risk marker | Original 4–6× association | At least annual screening; disease separately managed | 3-6, level 2 |
| Ancestry context | Skin colour is not individual genetic risk | Original 3× prevalence in darker-skinned groups; Latin American context | Combine clinical and population context | 3-9, level 1 |
| CDR | Interpret disc size and rim | ≥0.6: LR 7.0–7.5, diagnostic odds not future risk | Investigate suspicious discs | 3-12, level 1 |
| CDR asymmetry | Compare both eyes | ≥0.2: LR 3.9–4.1; ≥0.3: LR 7.3 | Investigate with function and structure | 3-13, level 1 |
| Steroids | Route, duration and preparation matter | Historical inhaled high-dose association; intranasal low group signal is not zero risk | Individual pressure monitoring, no self-discontinuation | 3-11, level 2 |
What are the main learning points?
Risk factors guide assessment, not a glaucoma diagnosis. The German screening intervals concern people without known glaucoma; manifest disease and diagnosed ocular hypertension need individual follow-up.
When is assessment urgent?
Sudden visual loss, severe eye pain, new field loss or marked pressure elevation needs prompt assessment rather than waiting for the next screening date.
References and access status
- 1Immutable original export; own complete lecture export
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 2DOG/BVA S2e 045-015, 3 March 2024
Selected extracted original PDF text read 15 November 2026: scope p1, incidence table p8, selected PEX/prevalence p13–14, steroids and disc findings p16–18, recommendations and intervals p19–27. Not the complete 34-page report or all cited studies; source table layout needs image confirmation.
- 3OHTS 2002; PMID 12049574
Historical full-text appraisal from review 005 on 2–6 October 2026 and Issue 161 notes reused; not newly read. Open treatment and masked endpoint assessment distinguished.
- 4Brandt et al. CCT-adjusted IOP and OHTS prediction. 2012; PMID 21705084
Historical review 005 full-text appraisal reused, with complete-case and delayed-CCT limits. Risk-model discrimination is not measurement accuracy; no new full-text claim.
For patients
Glaucoma can damage the optic nerve before you notice symptoms. An abnormal screening test leads to further tests; it does not automatically mean you have glaucoma.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
Sudden visual loss, severe eye pain, new field loss or marked pressure elevation needs prompt assessment rather than waiting for the next screening date.
Sudden visual loss, severe eye pain, new field loss or marked pressure elevation needs prompt assessment rather than waiting for the next screening date.